“One pill, once daily”: what clinicians need to know about Atripla™

Figures & data

Table 1 Adverse events occurring in ≥1% of persons on Atripla™ containing elements (Gallant et al 2006; Riddler et al 2006)

	GS-99-934 (through 48 weeks) (used all three elements of Atripla^®)	GS-99-903 (though 144 weeks) (lamivudine in place of emtricitabine)	ACTG 5142 (through 96 weeks) (lamivudine in place of emtricitabine, n = 85)
	N = 257	N = 296	N = 250 (all NRTI combinations)
Fasting cholesterol >240 mg/mL	15%	NR	NR
Creatine kinase M: >990 U/L and F: >845 U/L	7%	12%	NR
Serum amylase >175 U/L	7%	9%	NR
AST M: >180 U/L and F: >170 U/L	3%	5%	4% (>5x ULN)
ALT M: >215 U/L and F: >170 U/L	2%	4%	3% (>5x ULN)
Alkaline phosphatase >550 U/L	1%	NR	NR
Hemoglobin <8.0 mg/dL	0%	NR	NR
Hyperglycemia >250 mg/dL	1%	NR	NR
Hematuria >75 RBC/HPF	2%	6%	NR
Neutrophils	3%(<1000 mg/mm^3)	3%	5%(<750 mg/mm^3)
Fasting triglyceride >750 mg/dL	4%	3%	3%

Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; RBC/HPF, red blood cells per high power field; NRTI, nucleoside reverse transcriptase inhibitor.

GallantJEDeJesusEArribasJRTenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIVN Engl J Med20063542516016421366

 PubMed Web of Science ®Google Scholar

RiddlerSAHaubrichRDiRienzoGA prospective, randomized, phase III trial of NRTI-, PI-, and NNRTI-sparing regimens for initial treatment of HIV-1 infection: ACTG 5142Program and abstracts of the XVI International AIDS ConferenceAugust 13–18, 2006Toronto, Canada Abstract THLB0204

 Google Scholar